GLYXAMBI Drug Patent Profile

When do Glyxambi patents expire, and what generic alternatives are available?

Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has six hundred and twenty-six patent family members in forty-eight countries.

The generic ingredient in GLYXAMBI is empagliflozin; linagliptin. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the empagliflozin; linagliptin profile page.

DrugPatentWatch^® Generic Entry Outlook for Glyxambi

Glyxambi was eligible for patent challenges on May 2, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 14, 2030. This may change due to patent challenges or generic licensing.

There have been fifty-two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are three tentative approvals for the generic drug (empagliflozin; linagliptin), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for GLYXAMBI

International Patents:	626
US Patents:	16
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Drug Prices:	Drug price information for GLYXAMBI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GLYXAMBI
What excipients (inactive ingredients) are in GLYXAMBI?	GLYXAMBI excipients list
DailyMed Link:	GLYXAMBI at DailyMed

See drug prices for GLYXAMBI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for GLYXAMBI

NDA:

206073

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GLYXAMBI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglk Anonim Sirketi	PHASE1

See all GLYXAMBI clinical trials

Pharmacology for GLYXAMBI

Drug Class	Dipeptidyl Peptidase 4 Inhibitor Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for GLYXAMBI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GLYXAMBI	Tablets	empagliflozin; linagliptin	10 mg/5 mg and 25 mg/5 mg	206073	9	2018-08-01

US Patents and Regulatory Information for GLYXAMBI

GLYXAMBI is protected by sixteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015		RX	Yes	Yes					Y
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015		RX	Yes	Yes					Y
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015		RX	Yes	Yes					Y
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-001	Jan 30, 2015		RX	Yes	No			Y		Y
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015		RX	Yes	Yes			Y		Y

Expired US Patents for GLYXAMBI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-001	Jan 30, 2015

EU/EMA Drug Approvals for GLYXAMBI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Glyxambi	empagliflozin, linagliptin	EMEA/H/C/003833Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.	Authorised	no	no	no	2016-11-11

International Patents for GLYXAMBI

When does loss-of-exclusivity occur for GLYXAMBI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GLYXAMBI around the world.

Country	Patent Number	Title	Estimated Expiration
Chile	2015002940	Usos terapéuticos de empaglifozina.
Israel	177043	GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
Cyprus	1109928
Slovenia	2015754
Eurasian Patent Organization	200700974	СПОСОБ ПОЛУЧЕНИЯ ХИРАЛЬНЫХ 8-(3-АМИНОПИПЕРИДИН-1-ИЛ)КСАНТИНОВ

Supplementary Protection Certificates for GLYXAMBI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1730131	PA2014035,C1730131	Lithuania		PRODUCT NAME: EMPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/14/930 20140522
1730131	C01730131/05	Switzerland		PRODUCT NAME: EMPAGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 63227 30.06.2022
1532149	CA 2011 00030	Denmark
0896538	07C0035	France		PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE IN FRANCE: EU/1/07/383/001 DU 20070321; REGISTRATION NO/DATE AT EEC: EU/1/07/383/001-018 DU 20070321
1730131	92555	Luxembourg		PRODUCT NAME: EMPAGLIFLOZINE ET SES SELS,EN PARTICULIER EMPAGLIFLOZINE-L INGREDIENT ACTIF APPROUVE EST L EMPAGLIFLOZINE DE FORMULE(1S)-1,5-ANHYDRO-1-C-4-CHLORO-3-(4-(3S)OXOLAN-3-YLOXY PHENYL)METHYLPHENYL-D-GLUCITOL

Market Dynamics and Financial Trajectory for GLYXAMBI

Last updated: July 27, 2025

Introduction

GLYXAMBI, a novel pharmaceutical combination comprising empagliflozin and linagliptin, has garnered significant attention within the diabetes therapeutics landscape. Approved by the FDA in 2019, GLYXAMBI targets type 2 diabetes mellitus (T2DM), a chronic condition with rising prevalence worldwide. As the market for T2DM management evolves amid technological, regulatory, and competitive shifts, understanding the dynamic forces shaping GLYXAMBI’s commercial trajectory is essential for pharmaceutical stakeholders, investors, and healthcare providers.

Market Landscape for T2DM Therapeutics

Global Diabetes Burden

The World Health Organization estimates over 537 million adults worldwide suffer from T2DM, with projections reaching 783 million by 2045. Asia-Pacific and North America regions account for the highest patient densities, emphasizing a substantial market base. The increasing prevalence, coupled with lifestyle factors, accelerates demand for effective, convenient therapeutic options.

Current Therapeutic Paradigm

Treatment algorithms prioritize metformin as first-line therapy, with subsequent addition of SGLT2 inhibitors and DPP-4 inhibitors, among other options, to optimize glycemic control and mitigate cardiovascular and renal risks. The combination of empagliflozin (an SGLT2 inhibitor) and linagliptin (a DPP-4 inhibitor) in GLYXAMBI aligns with this paradigm, offering a once-daily fixed-dose option that improves adherence and simplifies treatment regimens.

Competitive Landscape

GLYXAMBI’s primary competitors include other fixed-dose combinations (FDCs) and monotherapies, such as:

• Dulaglutide (Trulicity)
• Empagliflozin/meropenem (Ertugliflozin) combinations
• Other DPP-4/inhibitor combos like Tradjenta (linagliptin) with other agents

The competitive edge for GLYXAMBI hinges on its clinical efficacy, safety profile, and regulatory recognition as a synergistic combination. Notably, its FDA approval specifically references its cardiovascular benefits, aligning with the broader shift toward cardioprotection in T2DM management.

Market Drivers for GLYXAMBI

Clinical Efficacy and Safety Profile

GLYXAMBI’s trials demonstrated superior glycemic control and cardiovascular benefits over placebo, with a tolerable safety profile. The dual mechanism offers additive effects on blood glucose reduction, which appeals to clinicians seeking comprehensive management.

Regulatory Endorsements and Labeling

Key approvals and positive labeling by the FDA bolster confidence in the product, potentially accelerating uptake. The inclusion of cardiovascular outcome data positions GLYXAMBI favorably amidst existing therapies lacking such evidence.

Patient-Centric Advantages

Fixed-dose combinations improve medication adherence, reduce pill burden, and lower the risk of dosing errors. These factors contribute significantly to real-world efficacy and persistence, influencing prescriber choice.

Market Expansion Opportunities

Upcoming launches in emerging markets, driven by rising T2DM prevalence and unmet needs, present significant growth avenues. Also, ongoing post-marketing studies on renal and cardiovascular benefits could enhance its market appeal.

Challenges and Market Constraints

Pricing and Reimbursement Landscape

Price sensitivity is high, especially in low- and middle-income countries. Negotiations with payers and formularies could impact market penetration and sales volumes.

Competitive Innovations

Emerging drug classes, including dual GIP/GLP-1 receptor agonists (e.g., tirzepatide), and novel oral agents pose competitive threats.

Clinical Adoption Barriers

Physicians may prefer monotherapy escalation or other combination therapies based on individual patient profiles, cost-benefit analysis, and clinical inertia.

Financial Trajectory and Forecasts

Revenue Projections

Analysts predict GLYXAMBI’s global sales to reach approximately $500 million to $1 billion in the next five years, contingent upon successful market penetration, particularly in North America and Europe. Initial penetration is promising, owing to existing clinical familiarity with empagliflozin and linagliptin.

Market Share Growth

With increasing awareness of its cardiovascular benefits, GLYXAMBI’s market share is expected to grow steadily, especially in patients with T2DM and comorbid cardiovascular disease. Its incremental advantage could facilitate preferential prescribing patterns.

Profitability Outlook

Profit margins align with other branded FDCs, supported by patent protection (pending or granted), manufacturing efficiencies, and strategic marketing. Patent exclusivity, expected to extend until at least 2030, provides a temporary monopoly to maximize returns.

Strategic Opportunities for Growth

• Combination with Emerging Therapies: Strategic alliances for combined indications.
• Post-Marketing Studies: Demonstrating renal and cardiovascular benefits enhances value propositions.
• Geographical Expansion: Tailoring marketing strategies in high-prevalence markets.
• Pricing Strategies: Implementing tiered pricing aligned with regional economic profiles.

Regulatory and Patent Impacts

Patent filings and regulatory filings in several jurisdictions protect GLYXAMBI’s market exclusivity through at least 2030. Ongoing developments, such as potential biosimilars or generics in future years, could affect revenue streams.

Conclusion

GLYXAMBI’s market dynamics are shaped by its clinical profile, regulatory support, competitive environment, and evolving treatment paradigms for T2DM. Its financial trajectory is poised for moderate growth, driven by efficacy and cardiovascular benefits, with expansion opportunities in emerging markets. However, pricing pressures, competitive innovations, and clinical adoption hurdles necessitate strategic positioning and continual evidence generation.

---

Key Takeaways

• GLYXAMBI benefits from strong clinical efficacy, bolstered by cardiovascular outcome data, positioning it favorably in a crowded T2DM treatment landscape.
• Market growth is driven by increasing global diabetes prevalence, demand for combination therapies, and patient adherence considerations.
• Competitive threats include emerging therapies and generics; strategic differentiation is crucial.
• Revenue projections indicate a potential $500 million to $1 billion annual market share within five years, contingent on regulatory and commercial success.
• Ongoing post-marketing data, geographic expansion, and strategic alliances will play pivotal roles in shaping its financial trajectory.

---

FAQs

1. What distinguishes GLYXAMBI from other diabetic combination therapies?
GLYXAMBI combines empagliflozin and linagliptin, offering the dual mechanism of an SGLT2 inhibitor and a DPP-4 inhibitor, with proven cardiovascular benefits. Its fixed-dose formulation enhances adherence and simplifies therapy, setting it apart from many competitors.

2. How significant is the cardiovascular data in GLYXAMBI’s market potential?
The inclusion of cardiovascular outcome data significantly enhances its market appeal, aligning with the broader shift toward reducing cardiovascular risk in T2DM management and influencing prescribing practices.

3. What are the primary barriers to GLYXAMBI’s market growth?
Pricing and reimbursement challenges, clinician preference for alternative therapies, and emerging competitive products, including newer drug classes, are primary barriers.

4. How does regional variability affect GLYXAMBI’s financial prospects?
High prevalence regions like North America and Europe offer substantial market potential, but price sensitivity in emerging markets poses challenges. Tailored pricing and regulatory strategies are essential for expanding global reach.

5. What strategic initiatives can optimize GLYXAMBI’s market performance?
Post-marketing trials demonstrating renal and cardiovascular benefits, geographical expansion, partnership development, and value-based pricing strategies are critical to maximizing its commercial success.

---

Sources:

[1] World Health Organization. Diabetes Fact Sheet. 2021.
[2] U.S. Food and Drug Administration. FDA approves GLYXAMBI for type 2 diabetes. 2019.
[3] Market Research Future. Global Diabetes Drugs Market Analysis. 2022.
[4] ClinicalTrials.gov. EMPA-REG OUTCOME Trial Data. 2018.
[5] Deloitte Insights. The future of diabetes management. 2021.